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cross-sectional analysis of 2005–2006 MEPS data involving children. Functional 
impairment was ascertained using the mean summated scores (range 0–52) of the 
parent-reported Columbia Impairment scale (CIS). Psychometric properties of the CIS 
were evaluated for the study sample. The Wilson and Cleary Model was used to 
examine the factors associated with functional impairment in children and adolescents. 
The primary independent variable of interest was depression. Multivariate linear 
regression involving the SURVEYREG procedure was applied to the study sample to 
identify the predictors of functional impairment in children and adolescents. 
RESULTS: Analysis of the CIS revealed that Cronbach’s alpha of the parent-reported 
CIS was 0.90 with item-to-total correlations ranging from 0.51 to 0.77. The mean 
summated CIS score of children and adolescents with depression (CIS, 19.88) was 
higher than those without depression (CIS, 6.09). Multivariate linear regression 
revealed that the interaction between age and depression was signiﬁcant and therefore 
stratiﬁed regression analysis was performed by age. In both age groups, the diagnosis 
of depression was strongly associated with functional impairment (+7 units in ages 
5–11 years, +11 units in ages 12–17 years). The presence of developmental, respiratory 
tract, attention deﬁcit, and anxiety disorders also increased functional impairment in 
children and adolescents. Family factors such as parents’ psychiatric illness, their 
highest education level and family living arrangement further contributed to impair-
ment in children. CONCLUSIONS: Functional impairment is signiﬁcant in pediatric 
depression and understanding of personal and family factors can play an important 
role in the assessment, management and treatment of depression.
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THE RELIABILITY AND VALIDITY OF THE CLEAR THINKING SCALE 
(CTS) AMONG PATIENTS DIAGNOSED WITH SCHIZOPHRENIA
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OBJECTIVES: Previous research has demonstrated that clear thinking is relevant to 
patients diagnosed with schizophrenia. We tested the reliability and validity of an 
experimental clear thinking scale (CTS) among a sample of outpatients diagnosed with 
schizophrenia. The CTS measures functioning across four sub-domains: staying orga-
nized (SO); making sense of the world (MS); feeling clear headed (CH); and expressing 
thoughts and feelings (TF). METHODS: Following item generation and reduction, 
cognitive interview were used to reﬁne the survey instrument. The scale was then 
ﬁelded to a sample of outpatients diagnosed with schizophrenia. The reliability and 
validity of the CTS and its four sub-domains was assessed using the Cronbach’s alpha 
and comparison to the Clyde mood scale (CMS) construct of “clear thinking”. 
RESULTS: Cognitive interviews (n = 12) identiﬁed several items that patients had 
difﬁculty understanding, which were subsequently removed or reworded. We also 
found that all items needed to be unidirectional and measuring deﬁcits (i.e., while clear 
thinking is a positive construct, patients related to it best in its absence). A sample of 
51 outpatients diagnosed with schizophrenia (66% male; average age = 49 y; average 
time since diagnosis = 22 y) completed the survey (only one respondent was unable 
to complete the survey. Cronbach’s alphas for all constructs were good: .77 (SO), .79 
(MS) .79 (CH), and .83 (TF), and was excellent for the overall scale (.93). All con-
structs were positively correlated with CMS clear thinking construct, which had a 
Cronbach’s alpha of .8, but these correlations were signiﬁcant only for TF (p = 0.002) 
and the overall scale (p = 0.02). CONCLUSIONS: Findings indicate that clear thinking 
can be reliably and validly described over four domains that are relevant to patients 
diagnosed with schizophrenia. Future research will focus on further reﬁning the CTS, 
comparing it with other scales of functioning and disease symptoms and assessing its 
sensitivity to changes.
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ANALYSIS OF ADOLESCENT PATIENTS WITH NON-DEPRESSIVE 
NEUROSES IN COMPARISON TO THE GENERAL INPATIENT GROUP
Houlette B
University of Louisville, Louisville, KY, USA
OBJECTIVES: To analyze a variety of variables for DRG 427, non-depressive neuro-
ses, in comparison to the control group to determine any trends or discrepancies. 
METHODS: The data were taken from the Kids’ Inpatient Database (KID) from year 
2007. This database describes hospital inpatient stays for children. To create a control 
group for comparison, a random sample of 8201 patients with DRG codes other than 
427 was taken. The control group combined with the experimental group, DRG code 
427, gives a total of 16,402 entries to examine. RESULTS: The diagnosis of non-
depressive neuroses was found to be much more prevalent in females than males. 
While the general inpatient group was only 47% female, the speciﬁc DRG group was 
57% female. Kernel density estimations revealed that the speciﬁc DRG group on 
average had shorter lengths of stay and lower total charges than the general inpatient 
group. A logistic regression performed showed that patient demographics and severity 
levels are all signiﬁcant in predicting whether a patient will be classiﬁed as general 
inpatient group or speciﬁc DRG group. Linear regressions also showed that both the 
APRDRG and Disease Staging Resource Demand severity indices are signiﬁcant in 
predicting a patient’s total charges and length of stay. A linear regression using the 
top 10 diagnosis and procedure codes to predict length of stay showed that these 
variables predict very little of the variability. CONCLUSIONS: From the initial sta-
tistical analyses, it is evident that the experimental group had more females than males 
and on average showed shorter lengths of stay and charges than the control group. 
Also, severity levels proved to be consistently signiﬁcant in predicting the control, 
length of stay, and total charges while patient demographics and diagnosis and pro-
cedure codes were only signiﬁcant in some models.
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ALCOHOL/DRUG ABUSE OR DEPENDENCE WITH COMPLICATIONS 
AND COMORBIDITIES
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OBJECTIVES: To conduct exploratory data analysis on DRG 521: alcohol/drug abuse 
or dependence with complications and comorbidities. Comparing DRG 521 to a 
control group will provide insights into statistical trends relating to this particular 
diagnosis. METHODS: The data used for this statistical analysis were obtained from 
The Kids’ Inpatient Database (KID) from 2007. KID is a national database containing 
information on hospital inpatient stays for children twenty years old and younger. In 
this database, there are 1,447 cases of DRG 521. For comparison purposes, a random 
sample equal in size was drawn from all DRG codes other than DRG 521. The statisti-
cal software, SAS, is used to analyze this data set. RESULTS: Initial statistical analyses 
have shown a greater proportion of whites in the experimental group (DRG 521), 
72%, compared to the control group with 61%. The overwhelming majority of the 
experimental group is in the higher age range of ﬁfteen to twenty years old, compared 
to the control group which has a uniform distribution across all ages. In addition, the 
experimental group contains a higher proportion of males, 55.8%, compared to the 
control group, 52%. CONCLUSIONS: Previous research has indicated that when 
individuals have comorbid conditions including drug/alcohol dependence and mental 
illnesses, males are more likely to be treated and seek treatment for substance depen-
dence whereas females are more likely to seek treatment for mental illnesses. This 
information could explain why more males are present in the experimental 
group,compared to the control group. In addition, adolescence and young adults are 
more likely to engage in risky behavior, which would explain the concentration of 
older individuals in the experimental group.
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Kennedy J1, Tien YY1, Cohen LJ2, Sclar DA3, Blodgett E1
1Washington State University, Spokane, WA, USA, 2Washington State University College of 
Pharmacy/Washington Institute for Me, Spokane, WA, USA, 3Washington State University, 
Pullman, WA, USA
OBJECTIVES: The objective of this study is to compare rates of hospitalization among 
patients receiving different classes of antipsychotics (SGAs, FGAs, both, or none) in 
a large, all-ages sample of both institutionalized and noninstutionalized Medicare 
beneﬁciaries. METHODS: We examined the 2005 Medicare Current Beneﬁciary 
Survey (MCBS) Cost and Use ﬁle Prescription Drug Event (PDE) module for 11,236 
survey participants. Antipsychotic utilization was characterized in terms of class: FGA 
(chlorpromazine, ﬂuphenazine, haloperidol, loxapine, perphenazine, thiothixene, thio-
ridazine, and triﬂuoperazine) or SGA (aripiprazole, clozapine, olanzapine, quetiapine, 
risperidone, and ziprasidone). Hospitalization was deﬁned in terms of whether a 
Medicare beneﬁciary was admitted to the hospital for any reason in 2005, and the 
number of hospital visits. RESULTS: About 3.5% of Medicare beneﬁciaries (1.3 
million) ﬁlled one or more prescriptions for an antipsychotic medication in 2005. 
Rates of all-cause hospitalization among Medicare beneﬁciaries were signiﬁcantly 
higher for SGA users than for FGA users: 38.9% of those who used only SGAs com-
pared to 31.0% of FGA-only users. Patients prescribed both FGAs and SGAs had the 
highest rate of hospitalization (60.7%), compared to 21.3% of nonusers. Controlling 
for demographic, socioeconomic, health, and disability variables, SGA users were over 
twice as likely (odds ratio, 2.2; 95% CI, 1.17–2.9), and combination users were over 
six times as likely (odds ratio, 6.3; 95% CI, 2.4–16.2) as nonusers to be hospitalized. 
The odds of FGA users being hospitalized were not signiﬁcantly different from nonus-
ers (odds ratio, 1.4; 95% CI, 0.7–2.8). CONCLUSIONS: This analysis offers provoca-
tive, but by no means conclusive evidence that SGAs as a class are not necessarily 
superior to FGAs in mitigating patient’s use of hospital services, Systematic analysis 
of this relationship with a longitudinal sample of Medicare beneﬁciaries is 
warranted.
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ANTIPSYCHOTIC USE IN SENIORS: AN ANALYSIS FOCUSING ON 
DRUG CLAIMS FROM 2001 TO 2007
Hunt J, Gaucher M
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OBJECTIVES: The majority of antipsychotic use in the elderly is to treat behavioural 
and psychological symptoms of dementia. New information on the safety of antipsy-
chotics in the elderly was released between 2000 and 2005. This analysis provides 
insight into antipsychotic use among seniors during this time period. METHODS: 
Claims level data from the National Prescription Drug Utilization Information System 
(NPDUIS) Database were analyzed for seniors on public drug programs in six Cana-
dian provinces between 2001–2002 and 2006–2007. This analysis looked at trends in 
antipsychotic use, including use by age and sex. Additional analyses focused on atypi-
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cal antipsychotics, including use and average daily dose by chemical, use in community 
and long-term care settings, as well as use among seniors with and without claims 
for anti-dementia drugs. RESULTS: The rate of antipsychotic use among seniors in 
all provinces grew from 4.3% in 2001–2002 to 5.0% in 2006–2007. The rate of 
growth of antipsychotic use slowed during the study period from an average of 5.2% 
per year between 2001–2002 to 1.0% between 2003–2004 and 2006–2007. Antipsy-
chotic use was highest among females and seniors 85 and older. There was a continued 
shift to the use of atypical agents from typical agents over the study period. In 
2006–2007, 37.7% of senior nursing home residents in three provinces had claims for 
atypical antipsychotics, compared to only 2.6% of seniors living in the community. 
When looking at only seniors with claims for anti-dementia drugs, use of atypical 
antipsychotics was higher among nursing home residents. CONCLUSIONS: 
This analysis provides insight into antipsychotic use among seniors. Antipsychotic 
use increased throughout the study period, although its rate of growth declined fol-
lowing the release of the new safety information. The rate of atypical antipsychotic 
use was higher in seniors living in nursing homes and in those taking anti-dementia 
drugs.
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OBJECTIVES: Examine arrest outcomes for adults with severe mental illness (SMI) 
treated with second generation atypical antipsychotics (SGAs), ﬁrst generation anti-
psychotics (FGAs) or no medication. METHODS: Continuous medication episodes 
lasting at least 60 days between 2004 and 2008 were examined (N individuals = 
36,519; N episodes = 222,928). Medication episodes were coded as: 1) SGA—clozap-
ine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or RLAI; 2) FGA—
any other antipsychotic medication; or 3) none. Outpatient services included at least 
one behavioral health visit every 30 days of an episode. Data are from Florida’s 
Medicaid program and Department of Law Enforcement. Arrest was modeled as a 
function of medication controlling for time, outpatient treatment, and relevant demo-
graphic and diagnostic characteristics using survival analysis. Models also adjusted 
for the baseline propensity to receive an SGA. RESULTS: Five percent of medication 
episodes contained an arrest. There was a trend (p = 0.10) for the main effect of SGA 
episodes to reduce arrests compared to FGA episodes; however, the interaction 
between outpatient services and SGA episodes was signiﬁcant (Hazard Ratio [HR]: 
0.80; 95% Conﬁdence Limits [CL]: 0.65–0.99; p < 0.05) such that at least one out-
patient visit every 30 days of an SGA episode reduced arrests compared to FGA 
episodes. Compared to no medication episodes, the interaction between outpatient 
treatment by SGA episodes reduced arrests (HR: 0.87; 95% CL: 0.76–0.99; p < 0.05) 
whereas outpatient treatment by FGA episodes did not reduce arrests. Substance 
abuse, medication gaps, and prior arrest increased risk of subsequent arrest. CON-
CLUSIONS: There was a statistically signiﬁcant interaction between outpatient visits 
and treatment that indicated an association between a reduced risk of arrest for SGAs 
compared to FGAs and no medication periods. These ﬁndings suggest the importance 
of both effective antipsychotic medications and outpatient interventions to reduce 
arrests in adults with SMI.
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HEALTH CARE EXPENDITURES IN PEDIATRIC POPULATION WITH 
DEPRESSION IN THE UNITED STATES
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OBJECTIVES: To examine the patterns and associated factors of health care expen-
ditures in the pediatric population with depression using 2005–2006 Medical Expen-
diture Panel Survey (MEPS) data. METHODS: Analysis was based on a nationally 
representative sample of children and adolescents aged 5 to 17 years with an ICD-
9-CM diagnosis of depression from the 2005–2006 MEPS. Multivariate model within 
the conceptual framework of Andersen’s Behavioral Model was used to examine 
factors related to health care expenditures in children and adolescents with depression. 
Smearing techniques were used to transform estimated log costs into actual costs. 
RESULTS: Analysis of annual expenditures in children and adolescents with depres-
sion revealed that average total and out-of pocket payments per child with depression 
were $3963 (95% CI 2453–5471) and $672 (95% CI 377–973), respectively. Pre-
scription-related expenditures in children and adolescents with depression revealed 
that average total and out-of pocket payments were $1096 (31% of total) and $343 
(51% of total), respectively. Multivariate model revealed that predisposing, enabling, 
and need factors were associated with total health expenditures. Among the predispos-
ing characteristics, age (+$3069) and family history of psychiatric disorders (+$2066) 
were positively associated with total expenditures. Among the enabling characteristics, 
children and adolescents having usual source of care provider had lower total expen-
ditures (−$3523) than those without usual source of care. Hyperactivity disorders 
(+$4001) and functional impairment (+$1304) increased total expenditures in children 
with depression. CONCLUSIONS: Analysis of MEPS data revealed prescription medi-
cations account for signiﬁcant portion of total and out-of-pocket expenditures. Pre-
disposing, enabling, and need factors play an important role in the overall burden of 
pediatric depression in the United States.
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COST OF PHARMACEUTICAL CARE IN PATIENTS WITH METABOLIC 
SYNDROMES CAUSED BY ATYPICAL ANTIPSYCHOTICS
Su HC, Chen CH, Chan AL
Chi-Mei medical center, Tainan, Taiwan
OBJECTIVES: The aim of this study was to evaluate the probability of metabolic 
syndrome caused by atypical antipsychotics after long term therapy and the cost of 
pharmacist interventions to improve these metabolic adverse effects. METHODS: A 
total of 431 adults prescribed atypical antipsychotics therapy from 2002 to 2007 were 
retrieved from the claim database. The primary outcome measurement was the prob-
ability of metabolic syndrome caused by atypical antipsychotics after long term 
therapy. The secondary outcome was to evaluate the cost of pharmacist intervention. 
Pharmacist consultation clinic for measuring their waist, buttocks, pharmaceutical 
education and body weight management. Computerized physician order entry alerting 
system for abnormal metabolic chemical variables remind physician to attend patients 
abnormal laboratory data and adjust the treatment regimen. RESULTS: The primary 
outcomes showed that the total rate of metabolic syndrome induced by atypical 
antipsychotics were 16% (48/298). The secondary outcome, the abnormal BMI value 
of 50 patients,who received pharmacist consultation services, decreased from 52% to 
41%. After establishment of computerized physician order entry alerting system, the 
possibility of patients’ abnormal biochemical values induced by atypical antipsychotics 
decreased from 4.28% (33/771) to 1.23% (8/651). The clinical effectiveness of this 
research included the occurrence of dyslipidaemia and disorders of glucose homeosta-
sis associated with cardiovascular disease. The total direct medical cost saved for this 
pharmaceutical care was approximately NT 1,428,250 during this study period. 
CONCLUSIONS: All patients receiving atypical antipsychotic agents associated with 
metabolic adverse events should be routinely monitored on weight gain, abnormal 
blood glucose and lipid levels. The effective communication and collaboration with 
mental health care and pharmaceutical care services is an effective model for caring 
patients with mental disease.
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IMPACT OF FDA ANTIDEPRESSANT BLACK BOX WARNING AND 
OTHER REGULATORY CHANGES ON PRESCRIPTION PATTERN FOR 
CHILDREN BY OFFICE BASED PHYSICIANS USING NATIONAL 
AMBULATORY MEDICAL CARE SURVEY (NAMCS)
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St. John’s University, Jamaica, NY, USA
OBJECTIVES: The aim of the study is to determine the impact of black box warning 
and other regulatory changes related to antidepressants on the prescription pattern of 
antidepressants for children and adolescents by ofﬁce based physicians. METHODS: 
Data for the present study was obtained from National Ambulatory Medical Care 
Survey (NAMCS), 2003–2005. Patients under the age of 18 were included in the study, 
if they had at least one antidepressant prescribed. Prescription pattern of antidepres-
sant was assessed in terms of rate of antidepressants prescribed, type of antidepres-
sants, physician specialty and demographics such as age, gender and race. Descriptive 
statistics were carried out using SPSS 17. RESULTS: The number of visits with at least 
one antidepressant prescribed for children and, adolescents were 228 (10.37%), 213 
(9.23%) and, 184 (6.81%) for year 2003, 2004 and 2005 respectively. Rate of pre-
scribing Fluoxetine per 100 antidepressants increased from 17.16 in 2003 to 19.13 in 
2004 and 26.26 in 2005, rate of prescribing Paroxetine decreased from 17.91 in 2003 
to 11.30 in 2004 to 11.11 in 2005. The number of antidepressants prescribed by 
psychiatrists decreased from (186, 81.6%) in 2003 to (164, 77%) in 2004 and (135, 
73.6%) in 2005. CONCLUSIONS: The rate of prescribing antidepressants to children 
and adolescents decreased after FDA black box warning in 2004. The prescription 
rate of Fluoxetine increased after FDA approved it for children and adolescents in 
2004 while prescription rate of Paroxetine decreased after 2003 when FDA recom-
mended that it shouldn’t be used in pediatric patients. No changes were observed in 
antidepressant prescribing by primary care physicians.
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AGE RELATED TREATMENT DIFFERENCES AMONG CHILDREN WITH 
BIPOLAR SPECTRUM DISORDERS
Dusetzina SB, Hansen R, Farley J, Weinberger M, Sleath B, Gaynes BN
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OBJECTIVES: To identify the extent to which psychotropic medication prescribing 
for bipolar spectrum disorders differs for younger children as compared with older 
children. Identifying if younger children receive similar diagnoses and treatments as 
older children is important, as this may inform clinical trial designs and the degree to 
which medication use in older children can be generalized to younger children. 
METHODS: A retrospective cohort was constructed using 2005–2007 MarketScan 
data. Patients under 18 years of age, with one inpatient or two outpatient insurance 
claims for any bipolar spectrum disorder were included. Patients whose pharmacy 
data were unavailable or who were not continuously insured from diagnosis to 30 
days after diagnosis were excluded. Ages 9 and under were considered “younger” 
and ages 10–17 were considered “older.” Medication use was summarized as therapies 
prescribed within 30 days after the last bipolar diagnosis. Psychotropic medication 
use included lithium, anticonvulsants, antipsychotics, antidepressants, or stimulants. 
RESULTS: Approximately 11,000 children were eligible for inclusion in each 
study year. In 2007, 64.1% of younger and 62.8% of older children received psycho-
tropic medications for bipolar disorder. Younger children were less likely than older 
children to receive lithium (8.2% versus 11.6%), anticonvulsants (36.2% versus 
